Skip to main content

Table 3 Patient demographics in the medical records review study

From: Panitumumab use in metastatic colorectal cancer and patterns of RAS testing: results from a Europe-wide physician survey and medical records review

  Rounds 1 & 2 Round 3 Total
All patients (N = 306) (N = 131) (N = 437)
Sex – male, n (%) 204 (66.7) 85 (64.9) 289 (66.1)
Age (years) – mean (SD) 66.4 (10.9) 64.3 (11.3) 65.8 (11.1)
  ≥ 65 years, n (%) 189 (61.8) 69 (52.7) 258 (59.0)
  ≥ 75 years, n (%) 73 (23.9) 27 (20.6) 100 (22.9)
Patients receiving concurrent oxaliplatina (N = 85) (N = 71) (N = 156)
Sex – male, n (%) 65 (76.5) 49 (69.0) 114 (73.1)
Age (years) – mean (SD) 63.8 (11.2) 63.6 (10.1) 63.7 (10.6)
  ≥ 65 years, n (%) 48 (56.5) 33 (46.5) 81 (51.9)
  ≥ 75 years, n (%) 15 (17.6) 10 (14.1) 25 (16.0)
  1. SD standard deviation
  2. aReceived oxaliplatin-containing chemotherapy during the interval from 7 days before the date of the first dose of panitumumab until 7 days after the last dose of panitumumab